We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesSana Biotechnology Inc

Sana Biotechnology Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
2.145 USD -0.14 ( 6.33%)
Last update at 2026-11-12T15:50:00Z
VOLUME
1319477
Market Cap
945.98M

Momentum Score

…

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.10
Low
2.25
High
52 Week Price Range
2.61
Low
6.55
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
2.29
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.49
ROE
-152.87%
Net Debt
6.99M
ROCE
-72.20%
Diluted EPS TTM
-0.74

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -244.17M -266.76M -283.25M -269.48M -355.93M
Net income -244.17M -266.76M -283.25M -266.39M -344.18M
Selling general administrative 44.30M 64.04M 73.30M 71.56M 50.41M
Selling and marketing expenses - - 73.23M - -
Gross profit -12.75M -15.49M -30.86M - -
Reconciled depreciation 12.75M 17.39M 24.56M 15.62M 11.07M
Ebit -244.17M -266.76M -283.25M -288.19M -367.98M
Ebitda -231.42M -249.37M -258.70M -272.56M -356.91M
Depreciation and amortization 12.75M 17.39M 24.56M 15.62M 11.07M
Non operating income net other - - - -0.67M 0.30M
Operating income -190.96M -272.72M -293.14M -272.56M -356.91M
Other operating expenses 190.96M 272.72M 293.14M 272.56M 356.91M
Interest expense - - - -15.62M 11.07M
Tax provision - - - - 0.00M
Interest income 3.85M 10.47M 9.94M 3.76M 0.68M
Net interest income 3.85M 10.47M 9.94M 3.76M 0.68M
Income tax expense - - - -3.09M -11.75M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 178.21M 272.72M 293.14M 272.56M 356.91M
Cost of revenue 12.75M 15.49M 30.86M - -
Total other income expense net -53.21M 5.96M 9.89M 3.09M 0.98M
Net income from continuing ops -244.17M -266.76M -283.25M -269.48M -355.93M
Net income applicable to common shares - - - -269.48M -355.93M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 416.89M 501.02M 565.30M 822.72M 1129.41M
Intangible assets 59.20M 59.20M 59.20M 59.20M 59.20M
Other current assets 10.29M 8.31M 4.49M 14.37M 7.11M
Total liab 256.01M 250.52M 277.79M 323.40M 400.90M
Total stockholder equity 160.88M 250.50M 287.51M 499.31M 728.50M
Other current liab 62.12M 27.69M 47.18M 96.25M 56.38M
Common stock 0.03M 0.02M 0.02M 0.02M 0.02M
Capital stock 0.03M 0.02M 0.02M 0.02M 0.02M
Retained earnings -1849.02M -1604.85M -1338.09M -1054.84M -785.36M
Other liab - - - 116.04M 199.89M
Good will 140.63M 140.63M 140.63M 140.63M 140.63M
Other assets - - - 9.01M 13.82M
Cash 71.87M 127.57M 137.35M 176.76M 253.03M
Total current liabilities 78.73M 45.43M 64.49M 111.50M 99.23M
Current deferred revenue - - - - 31.48M
Net debt 6.99M -33.37M -33.25M -68.51M -142.09M
Short term debt 14.94M 12.53M 13.20M 12.39M 9.16M
Short long term debt total 78.86M 94.20M 104.10M 108.25M 110.94M
Other stockholder equity 2009.85M 1855.32M 1625.64M 1558.46M 385.80M
Property plant equipment - - - 66.92M 65.46M
Total current assets 148.68M 160.81M 213.51M 444.44M 558.10M
Long term investments - - 0.00M 10.05M 195.88M
Net tangible assets - - - 299.49M 528.68M
Short term investments 66.51M 24.93M 71.68M 247.20M 297.97M
Accounts payable 1.67M 5.21M 4.11M 2.86M 2.22M
Accumulated other comprehensive income 0.03M 0.01M -0.06M -4.33M -1.37M
Common stock total equity - - - 0.02M 0.02M
Retained earnings total equity - - - -1054.84M -785.36M
Non currrent assets other 3.17M 5.12M 6.37M 9.01M 13.82M
Non current assets total 268.21M 340.21M 351.78M 378.28M 571.31M
Capital lease obligations 78.86M 94.20M 104.10M 108.25M 110.94M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -40.73M 17.45M 172.01M 231.44M -211.36M
Change to liabilities - - - 11.97M 5.57M
Total cashflows from investing activities -40.24M 17.45M 172.01M 210.56M -245.80M
Net borrowings 126.06M 7.74M 27.02M - -
Total cash from financing activities 128.73M 199.75M 31.65M 4.91M 631.75M
Change to operating activities - - - 6.48M 10.07M
Net income -244.17M -266.76M -283.25M -269.48M -355.93M
Change in cash -55.33M -5.95M -49.92M -74.58M 134.90M
Begin period cash flow 131.40M 137.35M 187.27M 261.85M 126.95M
End period cash flow 76.06M 131.40M 137.35M 187.27M 261.85M
Total cash from operating activities -143.83M -223.15M -253.58M -290.05M -251.05M
Issuance of capital stock - 181.00M 31.65M 0.60M 626.40M
Depreciation 12.75M 15.50M 24.56M 15.62M 11.07M
Other cashflows from investing activities 1.43M 17.45M 0.19M - -4.57M
Sale purchase of stock - - - 0.60M 626.40M
Other cashflows from financing activities 128.73M -181.00M 172.01M 4.31M 5.35M
Change to netincome - - - 25.67M 51.13M
Capital expenditures 0.94M 33.43M 20.03M 20.88M 29.86M
Cash flows other operating - - - -73.84M 37.10M
Cash and cash equivalents changes - - - -74.58M 134.90M
Change in working capital -10.11M -1.19M 18.61M 7.54M 9.80M
Stock based compensation 25.46M 37.68M 35.53M 38.34M 22.36M
Other non cash items 72.24M -8.39M -49.03M -82.08M 61.64M
Free cash flow -144.77M -256.58M -273.61M -310.93M -280.92M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
SANA
Sana Biotechnology Inc		 -0.14
6.33%		 2.15 - - - 6.20 -1.08
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

188 East Blaine Street, Seattle, WA, United States, 98102

206 701 7914

https://www.sana.com

142

Name Title Year Born
Dr. Steven D. Harr M.D. Pres, CEO & Director 1970
Dr. Richard C. Mulligan Ph.D. Exec. Vice Chairman & Head of SanaX 1955
Mr. Nathan Hardy M.B.A. Exec. VP & CFO 1976
Dr. Sunil Agarwal M.D. Exec. VP, Head of Devel. & Chief Medical Officer 1970
Ms. Shanna Clouse Peek Sr. VP & Head of Corp. Operations NA
Brittany Mccleery Accounting Mang. NA
Dr. Edward Rebar Ph.D. Sr. VP & CTO 1968
Mr. Bernard J. Cassidy J.D. Exec. VP & Gen. Counsel 1955
Ms. Robin Andrulevich Exec. VP & Chief People Officer 1966
Mr. Paul Brunetta M.D. Sr. VP and Head of Clinical & Translational Science NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…